Drug, across the briefings
Sugemalimab across 9 cancers
Sugemalimab appears in 9 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Anal cancer | approved on CD274 | — | — | |
| Bladder cancer | approved on CD274 | — | — | |
| Cervical cancer | approved on CD274 | 1 | 1 | |
| Esophageal cancer | approved on CD274 | 1 | 1 | |
| Gastric cancer | approved on CD274 | — | — | |
| Head and neck cancer | approved on CD274 | 1 | 1 | |
| Hodgkin lymphoma | approved on CD274 | 1 | 1 | |
| Kidney cancer | approved on CD274 | — | — | |
| Lung cancer | approved on CD274 | 9 | 8 |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.